The radiosensitivity of malignant melanomas part II: Clinical studies

Trott, Klaus R.; Lieven, H. von; Kummermehr, J.; D, Skopal; Lukacs, Stefan; Braun‐Falco, Otto; Kellerer, Albrecht M.

doi:10.1016/0360-3016(81)90054-7

Cited by 78 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27 There has been a dogma that malignant melanoma is radioresistant. 27,45 Some in vitroradiobiological 4 and clinical studies, 2,19,27,36,39,41,46,[52][53] however, have demonstrated that radiotherapy may have a beneficial effect in locoregional control. The clinical studies were based on the in vitroinvestigation by Barranco 4 , which revealed a large, curvy shoulder with a relatively steep terminal slope in the survival curves of three human melanoma cell lines.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Malignant mucosal melanoma of the head and neck — a review

Lengyel

Gilde

Remenár

et al. 2003

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

“…2,19,41,[52][53] Different fractionation schedules have been used, e.g. 5 x 6 Gy twice a week 2 , 8 x 5 Gy/twice a week, 41 or 4 x 8 Gy once-a-week.…”

Section: Introductionmentioning

confidence: 99%

Malignant mucosal melanoma of the head and neck — a review

Lengyel

Gilde

Remenár

et al. 2003

Pathol. Oncol. Res.

View full text Add to dashboard Cite

“…(36) If instead the dose per fraction is kept constant the normalized response gradient is reduced simply to:…”

Section: Dose Response Relationmentioning

confidence: 99%

Dosimetric Precision Requirements in Radiation Therapy

Brahme

1984

Acta Radiologica: Oncology

460

224

View full text Add to dashboard Cite

“…Als Endpunkte gelten Tumorremission und Überleben [1,2,6,10,19,27,34]; nur wenige Studien untersuchen die möglichen Prognosefaktoren multifaktoriell [6,34,40]. Balch et al [6] fanden als ungünstige Parameter für schlechtes Ansprechen und kurzes Überleben ein Intervall <1 Jahr von Diagnose bis zur ersten Metastase, multiple/viszerale Metastasen; Alter, Geschlecht, Lokalisation und zeldosen auf ein besseres Ansprechen als bei konventionell fraktionierter RT hin; dem widersprechen mono- [17,30,47] und multizentrische Studien [41]. In unserer Studie war die RT-Gesamtdosis univariat ein Prognosefaktor, multivariat wurde dies nicht bestätigt.…”

Section: Besprechungunclassified

Langzeitergebnisse nach Strahlentherapie beim lokal rezidivierten und metastasierten malignen Melanom

et al. 1999

View full text Add to dashboard Cite

The 20-year radiotherapy (RT) experience in patients with locally advanced, recurrent or metastatic malignant melanoma (MM) is analyzed with respect to different endpoints and prognostic factors. From 1977 to 1995, 2917 consecutive patients were entered in our MM registry. RT was indicated in 121 patients (56 females, 65 males) for palliation in advanced MM stages. The histology of the primary lesion was nodular in 51, superficial spreading in 35, acral-lentiginous in 8 and lentigo maligna in 4 patients); 22 were missing or could not be reclassified. Eleven patients had primary or recurrent lesions which were ineligible for surgery or had residual disease (R2) after resection of a primary or recurrent lesion (UICC IIB); 57 patients had lymph node (33) or in-transit metastases (24) (UICC III), 53 had distant organ metastases (7 M1a; 46 M1b) (UICC IV). Time from first diagnosis to on-study RT averaged 19 (median: 18; range: 3-186) months. In most cases conventional RT was applied (2-6 Gy single fractions) up to a mean total RT dose of 45 (median: 48; range: 20-66) Gy. At 3 months follow-up (FU), complete response (CR) was achieved in 7 (64%) and overall response (CR+PR) in all (100%) UICC IIB patients, in 25 (44%)/44 (77%) of 57 UICC III patients, and in 9 (17%)/26 (49%) of 53 UICC IV patients. Progression during RT occurred in 25 (21%) patients. Patients with CR survived longer (median: 40 months) than those without CR (median: 10 months) (p<0. 01). At last FU, 26 patients were alive: 6 (55%) UICC IIB, 17 (30%) UICC III, and 3 (6%) UICC IV patients (p<0.01). In univariate analysis following favorable prognostic factors for CR and long-term survival were identified: low UICC stage (p<0.001), primary site head and neck and total dose >40 Gy (all p<0).

show abstract

The radiosensitivity of malignant melanomas part II: Clinical studies

Cited by 78 publications

References 7 publications

Malignant mucosal melanoma of the head and neck — a review

Malignant mucosal melanoma of the head and neck — a review

Dosimetric Precision Requirements in Radiation Therapy

Langzeitergebnisse nach Strahlentherapie beim lokal rezidivierten und metastasierten malignen Melanom

Contact Info

Product

Resources

About